# Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy

> **NCT05001971** · PHASE2 · COMPLETED · sponsor: **Hunan Cancer Hospital** · enrollment: 65 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib Plus Penpulimab

## Key facts

- **NCT ID:** NCT05001971
- **Lead sponsor:** Hunan Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-30
- **Primary completion:** 2025-01-21
- **Final completion:** 2025-04-15
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05001971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05001971, "Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05001971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*